Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study

Abstract Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) was Food and Drug Administration approved in February 2018. The paucity of real-world data prompted this retrospective, observational evaluation of discontinuation rates, adverse effects, and virologic control. In a Southern...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Open Forum Infectious Diseases 2020-09, Vol.7 (9), p.ofaa285-ofaa285
Hauptverfasser:	Hayes, Edwin, Derrick, Caroline, Smalls, Danielle, Smith, Hilary, Kremer, Nicole, Weissman, Sharon
Format:	Artikel
Sprache:	eng
Schlagworte:	African Americans Anti-HIV agents Antiviral agents Brief Report Complications and side effects Highly active antiretroviral therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!